代谢改善介导GLP-1受体激动剂与心肌梗死的因果关联:孟德尔随机化与中介分析研究
本研究采用孟德尔随机化(MR)和两步MR分析,以GLP-1受体表达遗传变异为工具变量,探讨GLP-1受体激动剂(GLP-1RAs)与心肌梗死(MI)的因果关联,并量化代谢改善的中介作用。结果显示,较高的GLP-1R表达与较低的2型糖尿病(OR 0.94 [95% CI 0.92, 0.97])和MI风险(OR 0.97 [95% CI 0.95, 1.00])相关;代谢改善介导了该关联,其中HbA1c介导36.67% [3.89, 69.44],BMI介导28.86% [2.62, 55.10]。调整代谢特征后,未观察到GLP-1R表达对MI的直接效应(β = -0.003,P = 0.12)。
要点
- GLP-1R表达升高与T2DM和MI风险降低相关。
- 代谢改善介导了GLP-1R表达对MI的保护作用,HbA1c和BMI贡献较大。
- 调整代谢特征后未见GLP-1R表达对MI的直接效应。
核心结论
- GLP-1RAs主要通过代谢改善发挥对MI的保护作用,独立于这些通路的直接效应未观察到。
研究设计与样本
- 采用孟德尔随机化(MR)评估GLP-1RAs与MI的因果关联,并用两步MR量化代谢特征的中介作用。
- 以与GLP-1受体表达相关的遗传变异作为工具变量(代理GLP-1RAs)。
- 代谢特征(HbA1c、BMI、血脂、血压)的GWAS数据来自Million Veteran Program,作为中介变量。
- T2DM的GWAS数据来自DIAGRAM联盟,MI的GWAS数据来自UK Biobank/CARDIoGRAMplusC4D,作为结局。
- 所有GWAS数据均限于欧洲 ancestry。
主要发现
- 较高的GLP-1R表达与较低的T2DM风险相关(OR 0.94 [95% CI 0.92, 0.97])。
- 较高的GLP-1R表达与较低的MI风险相关(OR 0.97 [95% CI 0.95, 1.00])。
- HbA1c介导36.67% [3.89, 69.44]的关联,BMI介导28.86% [2.62, 55.10]。
- 甘油三酯介导18.52% [1.47, 35.57],HDL胆固醇介导18.28% [1.45, 35.12]。
- 收缩压介导11.55% [0.33, 22.76];调整代谢特征后,GLP-1R表达对MI无直接效应(β = -0.003,P = 0.12)。
临床怎么用
- GLP-1RAs的心血管获益可能主要通过改善代谢实现,临床应重视代谢指标的综合管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have cardiovascular benefits, but whether this is via metabolic improvements or direct effect remains controversial. This study aimed to explore the causal link between GLP-1RAs and myocardial infarction (MI) and quantify the contribution of metabolic improvements. RESEARCH DESIGN AND METHODS: Mendelian randomization (MR) was applied to assess the causal relationship between GLP-1RAs and MI, and two-step MR analysis was applied to quantify the mediating role of metabolic traits. The direct effect of GLP-1RAs on MI was evaluated by multivariate Mendelian randomization (MVMR). Genetic variants associated with GLP-1 receptor (GLP-1R) expression (proxying GLP-1RAs) were used as instrumental variables. Genome-wide association studies (GWAS) data for metabolic traits glycated hemoglobin (HbA1c), BMI, lipid profile, and blood pressure were sourced from the Million Veteran Program, serving as mediators. GWAS data for type 2 diabetes mellitus (T2DM) were obtained from the DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) consortium, and data for MI were sourced from the UK Biobank/Coronary ARtery DIsease Genome wide Replication and Meta-analysis plus The Coronary Artery Disease (CARDIoGRAMplusC4D), serving as outcomes. All GWAS data were restricted to European ancestry. RESULTS: Higher GLP-1R expression was correlated with a lower risk of T2DM (odds ratio 0.94 [95% CI 0.92, 0.97]) and MI (0.97 [0.95, 1.00]). Metabolic improvements mediated this association: HbA1c (36.67% [3.89, 69.44]), BMI (28.86% [2.62, 55.10]), triglycerides (18.52% [1.47, 35.57]), HDL-cholesterol (18.28% [1.45, 35.12]), and systolic blood pressure (11.55% [0.33, 22.76]). No direct effect of GLP-1R expression on MI was observed after adjusting for metabolic traits (β = -0.003, P = 0.12). CONCLUSIONS: GLP-1RAs protect against MI primarily through metabolic improvements, with no direct effect independent of these pathways. These findings support prioritizing metabolic improvements to reduce cardiovascular risk with GLP-1RAs.
引用
- Tong J, Li N, Hu F, et al. Metabolic Improvement Mediates the Causal Relationship Between GLP-1 Receptor Agonists and Myocardial Infarction: A Mendelian Randomization and Mediation Analysis Study. Diabetes Care. 2026. PMID: 41259721. doi:10.2337/dc25-1822
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。